Ally Bridge Group LLC

Hedge Fund • Sector

Ally Bridge Group LLC is a Sector-focused Hedge Fund based in New York, NY led by Slanix Paul T Alex, reporting $167.9M in AUM as of Q3 2025 with 84% Healthcare concentration, 79% concentrated in top 10 holdings, and 17% allocation to SLNO.

PresidentSlanix Paul T Alex

Portfolio Value: $119.4M
Positions: 18
Top Holding: SLNO at 17.12%
Last Reported: Q3 2025

Address430 Park Avenue, 12th Floor, New York, NY, 10022, United States

Top Holdings

Largest long holdings in Ally Bridge Group LLC's portfolio (79.2% of total portfolio)

See all holdings

GthenH

Holding	Sector	Position	Weight	Traded	Ownership	Owned Since
1 Soleno Therapeutics SLNO	Biotechnology Healthcare	$20.4M	17.12%	+$8.4M Bought	0.57% 302.5K shares	Q4 2023 Held for 1y 11m
2 Madrigal Pharmaceuticals, Inc. MDGL	Biotechnology Healthcare	$15.0M	12.54%	+$15.0M Bought	0.15% 32.7K shares	Q3 2025 Held for 2 months
3 Atai Life Sciences ATAI	Biotechnology Healthcare	$12.1M	10.13%	+$12.1M New	0.98% 2.3M shares	Q3 2025 Held for 2 months
4 ASND Ascendis Pharma ASND	Unknown Unknown	$10.2M	8.50%	+$10.2M New	— 51.1K shares	Q3 2025 Held for 2 months
5 LENZ Therapeutics, Inc. LENZ	Biotechnology Healthcare	$8.2M	6.84%	-$7.8M Sold	0.61% 175.4K shares	Q2 2025 Held for 5 months
6 Taysha Gene Therapies, Inc. TSHA	Biotechnology Healthcare	$6.2M	5.20%	+$6.2M New	0.70% 1.9M shares	Q3 2025 Held for 2 months
7 Amylyx Pharmaceuticals, Inc. AMLX	Biotechnology Healthcare	$5.9M	4.98%	+$5.9M Bought	0.41% 437.4K shares	Q3 2025 Held for 2 months
8 CMPS Compass Pathways CMPS	Unknown Unknown	$5.9M	4.92%	+$5.9M New	— 1.0M shares	Q3 2025 Held for 2 months
9 Eupraxia Pharmaceuticals EPRX	Biotechnology Healthcare	$5.4M	4.52%	+$5.4M New	— 915.0K shares	Q3 2025 Held for 2 months
10 Monopar Therapeutics MNPR	Biotechnology Healthcare	$5.3M	4.41%	+$2.4M Bought	1.04% 64.5K shares	Q2 2025 Held for 5 months

See all holdings

GthenH

Changes

Portfolio activity, position movements, and quarter-over-quarter changes in Ally Bridge Group LLC's latest filing

See all changes

GthenC

Market Value

$119.4M

Prior: $110.2M

Q/Q Change

+8.38%

+$9.2M

Net Flows % of MV

-18.97%

Turnover Ratio

67.88%

New Purchases

7 stocks

$46.4M

Added To

3 stocks

+$12.9M

Sold Out Of

13 stocks

$65.3M

Reduced Holdings

6 stocks

-$19.2M

Increased Positions

Position	Shares Δ	Change
1 Atai Life Sciences ATAI	New	0 → 2.3M +$12.1M
2 ASND Ascendis Pharma ASND	New	0 → 51.1K +$10.2M
3 Taysha Gene Therapies, Inc. TSHA	New	0 → 1.9M +$6.2M
4 CMPS Compass Pathways CMPS	New	0 → 1.0M +$5.9M
5 Eupraxia Pharmaceuticals EPRX	New	0 → 915.0K +$5.4M

Decreased Positions

Position	Shares Δ	Change
1 VRNA Verona Pharma VRNA	Sold	160.7K → 0 −$15.2M
2 Merus N.V. MRUS	Sold	140.2K → 0 −$7.4M
3 Enliven Therapeutics ELVN	Sold	281.4K → 0 −$5.6M
4 Oric Pharmaceuticals, Inc. ORIC	Sold	485.6K → 0 −$4.9M
5 Replimune Group REPL	Sold	528.5K → 0 −$4.9M